Comparative Pharmacology
Head-to-head clinical analysis: AMINESS 5 2 ESSENTIAL AMINO ACIDS W HISTADINE versus TRAVASOL 4 25 IN DEXTROSE 10 IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AMINESS 5 2 ESSENTIAL AMINO ACIDS W HISTADINE versus TRAVASOL 4 25 IN DEXTROSE 10 IN PLASTIC CONTAINER.
AMINESS 5.2% ESSENTIAL AMINO ACIDS W/ HISTADINE vs TRAVASOL 4.25% IN DEXTROSE 10% IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Provides essential amino acids and histidine for protein synthesis in patients unable to tolerate oral or enteral nutrition, supporting nitrogen balance and tissue repair. The amino acids are utilized for anabolic processes and metabolic pathways.
Provides parenteral nutrition with amino acids and dextrose to maintain nitrogen balance and provide caloric support in patients unable to tolerate oral or enteral feeding.
Intravenous infusion: 500 mL of 5.2% solution (26 g amino acids) over 8-12 hours daily, providing 0.8-1.2 g/kg/day of amino acids depending on metabolic needs.
Intravenous infusion: 1.5 to 2.5 g amino acids/kg body weight per day (equivalent to 35-60 mL/kg per day of TRAVASOL 4.25% IN DEXTROSE 10%) as part of total parenteral nutrition. Infusion rate should not exceed 0.2 g amino acids/kg per hour.
None Documented
None Documented
Approximately 2-4 hours for most essential amino acids; clinical context: rapid clearance necessitates continuous infusion for stable plasma levels.
Not applicable as a single entity; amino acids have rapid clearance (minutes to hours), dextrose half-life <15 minutes under normal conditions.
Renal: >95% as amino acids and metabolites; negligible biliary/fecal.
Amino acids are deaminated, with nitrogen excreted primarily as urea in urine (90-95%); small amounts excreted in feces (<5%) and bile (<1%). Dextrose is metabolized to CO2 and water.
Category C
Category C
Parenteral Nutrition Solution
Parenteral Nutrition Solution